providing a voice for Hawaii's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 1996
Meetings & Education
HSCO Patient Education Videos
State & Federal Resources
Off-Label Use Literature
Patient Advocacy Organizations
National Professional Organizations
Medical Aid in Dying
HSCO Corporate Members
Become a Supporter
Industry News Archive
FDA Approves Ibrutinib Plus Rituximab for Rare Blood Cancer
On August 27, AbbVie announced that the FDA has approved ibrutinib (Imbruvica) (Pharmacyclics, LLC) plus rituximab for the treatment of adult patients with Waldenström's macroglobulinemia (WM), a rare and incurable type of non-Hodgkin's lymphoma (NHL). This approval represents the first and only chemotherapy-free combination treatment specifically indicated for the disease.
Read the full AbbVie corporate press release here.
Tweets by HI_Oncology